🚀 VC round data is live in beta, check it out!
ODI Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for ODI Pharma and similar public comparables like BioAtla, MetaVia, Acurx Pharmaceuticals, Gelteq and more.
ODI Pharma Overview
About ODI Pharma
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
Founded
2019
HQ
Employees
1
Website
Sectors
Financials (FY)
EV
$7M
ODI Pharma Financials
ODI Pharma reported last fiscal year revenue of $338K and negative EBITDA of ($560K).
In the same fiscal year, ODI Pharma generated $91K in gross profit, ($560K) in EBITDA losses, and had net loss of ($640K).
ODI Pharma P&L
In the most recent fiscal year, ODI Pharma reported revenue of $338K and EBITDA of ($560K).
ODI Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $338K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $91K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($560K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (165%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (174%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($640K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (189%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ODI Pharma Stock Performance
ODI Pharma has current market cap of $7M, and enterprise value of $7M.
Market Cap Evolution
ODI Pharma's stock price is $0.40.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7M | $7M | 0.2% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialODI Pharma Valuation Multiples
ODI Pharma trades at 20.0x EV/Revenue multiple, and (12.1x) EV/EBITDA.
ODI Pharma Financial Valuation Multiples
As of April 12, 2026, ODI Pharma has market cap of $7M and EV of $7M.
Equity research analysts estimate ODI Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ODI Pharma has a P/E ratio of (11.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 20.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (12.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (11.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 74.8x | XXX | XXX | XXX |
| P/E | — | XXX | (11.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (19.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ODI Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ODI Pharma Margins & Growth Rates
ODI Pharma's revenue in the last fiscal year declined by (75%).
ODI Pharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.
ODI Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (75%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (165%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 120% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 201% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ODI Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioAtla | XXX | XXX | XXX | XXX | XXX | XXX |
| MetaVia | XXX | XXX | XXX | XXX | XXX | XXX |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Gelteq | XXX | XXX | XXX | XXX | XXX | XXX |
| Chosa Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ODI Pharma M&A Activity
ODI Pharma acquired XXX companies to date.
Last acquisition by ODI Pharma was on XXXXXXXX, XXXXX. ODI Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ODI Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialODI Pharma Investment Activity
ODI Pharma invested in XXX companies to date.
ODI Pharma made its latest investment on XXXXXXXX, XXXXX. ODI Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ODI Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ODI Pharma
| When was ODI Pharma founded? | ODI Pharma was founded in 2019. |
| Where is ODI Pharma headquartered? | ODI Pharma is headquartered in Sweden. |
| How many employees does ODI Pharma have? | As of today, ODI Pharma has over 1 employees. |
| Is ODI Pharma publicly listed? | Yes, ODI Pharma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of ODI Pharma? | ODI Pharma trades under ODI ticker. |
| When did ODI Pharma go public? | ODI Pharma went public in 2020. |
| Who are competitors of ODI Pharma? | ODI Pharma main competitors are BioAtla, MetaVia, Acurx Pharmaceuticals, Gelteq. |
| What is the current market cap of ODI Pharma? | ODI Pharma's current market cap is $7M. |
| What is the current revenue of ODI Pharma? | ODI Pharma's last fiscal year revenue is $338K. |
| What is the current EV/Revenue multiple of ODI Pharma? | Current revenue multiple of ODI Pharma is 20.0x. |
| Is ODI Pharma profitable? | No, ODI Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.